Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€24.59

€24.59

2.160%
0.52
2.160%
-
 
15:19 / Tradegate WKN: A2PLU4 / Name: Capricor / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Capricor

sharewise wants to provide you with the best news and tools for Capricor, so we directly link to the best financial data sources.

News

Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review

Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story: https://cdn.content.foolcdn.com/images/1umn9qeh/production/0fe050b5d35dffd742b195c313bda291f30dfea0-1401x1251.png?w=800&q=75&fit=max&auto=format
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story

Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), exercised 25,000 options for common stock and immediately sold the resulting shares for a transaction value of

Here's Why This Biotechnology Skyrocketed by 439% in December
Here's Why This Biotechnology Skyrocketed by 439% in December

Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of